The company's lead product is oral lasmiditan, a new chemical entity designed to deliver efficacy without the vasoconstrictor effects of previous therapies. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway and is a member of a novel drug class called "ditans." CoLucid has successfully completed seven clinical studies for lasmiditan, including a Phase 2b study treating a single migraine attack in 391 patients, achieving its primary endpoint of reducing a moderate or severe headache at baseline to mild or none 2 hours after dosing.